Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder.

Rodriguez Pena MDC, Tregnago AC, Eich ML, Springer S, Wang Y, Taheri D, Ertoy D, Fujita K, Bezerra SM, Cunha IW, Raspollini MR, Yu L, Bivalacqua TJ, Papadopoulos N, Kinzler KW, Vogelstein B, Netto GJ.

Virchows Arch. 2017 Dec;471(6):761-767. doi: 10.1007/s00428-017-2164-5. Epub 2017 Jun 8.

PMID:
28597078
2.

Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.

Wang CC, Huang CY, Jhuang YL, Chen CC, Jeng YM.

Histopathology. 2018 Apr;72(5):795-803. doi: 10.1111/his.13441. Epub 2018 Jan 4.

PMID:
29193225
3.

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S.

Hum Pathol. 2012 Oct;43(10):1573-82. doi: 10.1016/j.humpath.2011.10.026. Epub 2012 Mar 12.

PMID:
22417847
4.

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

López-Knowles E, Hernández S, Malats N, Kogevinas M, Lloreta J, Carrato A, Tardón A, Serra C, Real FX.

Cancer Res. 2006 Aug 1;66(15):7401-4.

5.

FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.

Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Jaramillo R, Amorós A, Tardón A, García-Closas R, Serra C, Carrato A, Malats N, Real FX.

Clin Cancer Res. 2005 Aug 1;11(15):5444-50.

6.

Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder.

Cowan ML, Springer S, Nguyen D, Taheri D, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, Del Carmen Rodriguez Pena M, VandenBussche CJ, Olson MT, Cunha I, Fujita K, Ertoy D, Kinzler K, Bivalacqua T, Papadopoulos N, Vogelstein B, Netto GJ.

Hum Pathol. 2016 Jul;53:8-13. doi: 10.1016/j.humpath.2016.02.009. Epub 2016 Mar 10.

7.

TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.

Wang K, Liu T, Liu C, Meng Y, Yuan X, Liu L, Ge N, Liu J, Wang C, Ren H, Yan K, Hu S, Xu Z, Fan Y, Xu D.

Oncologist. 2015 Mar;20(3):263-9. doi: 10.1634/theoncologist.2014-0391. Epub 2015 Feb 5.

8.

High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder.

Cowan M, Springer S, Nguyen D, Taheri D, Guner G, Rodriguez MA, Wang Y, Kinde I, VandenBussche CJ, Olson MT, Cunha I, Fujita K, Ertoy D, Bivalacqua TJ, Kinzler K, Vogelstein B, Netto GJ, Papadopoulos N.

Mod Pathol. 2016 May;29(5):511-5. doi: 10.1038/modpathol.2016.53. Epub 2016 Mar 11.

9.

Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.

Critelli R, Fasanelli F, Oderda M, Polidoro S, Assumma MB, Viberti C, Preto M, Gontero P, Cucchiarale G, Lurkin I, Zwarthoff EC, Vineis P, Sacerdote C, Matullo G, Naccarati A.

Oncotarget. 2016 Oct 11;7(41):67435-67448. doi: 10.18632/oncotarget.11883.

10.
11.

Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.

Kurtis B, Zhuge J, Ojaimi C, Ye F, Cai D, Zhang D, Fallon JT, Zhong M.

Ann Diagn Pathol. 2016 Apr;21:7-11. doi: 10.1016/j.anndiagpath.2015.12.002. Epub 2015 Dec 17.

PMID:
27040924
12.

High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.

Nguyen D, Taheri D, Springer S, Cowan M, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, VandenBussche CJ, Olson MT, Ricardo BF, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ.

Virchows Arch. 2016 Oct;469(4):427-34. doi: 10.1007/s00428-016-2001-2. Epub 2016 Aug 12.

13.

Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.

Downes MR, Weening B, van Rhijn BW, Have CL, Treurniet KM, van der Kwast TH.

Histopathology. 2017 Jan;70(2):281-289. doi: 10.1111/his.13063. Epub 2016 Oct 28.

PMID:
27530957
14.

TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.

Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ.

Cancer Res. 2013 Dec 15;73(24):7162-7. doi: 10.1158/0008-5472.CAN-13-2498. Epub 2013 Oct 11.

15.

Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.

Moss TJ, Qi Y, Xi L, Peng B, Kim TB, Ezzedine NE, Mosqueda ME, Guo CC, Czerniak BA, Ittmann M, Wheeler DA, Lerner SP, Matin SF.

Eur Urol. 2017 Oct;72(4):641-649. doi: 10.1016/j.eururo.2017.05.048. Epub 2017 Jun 7.

PMID:
28601352
16.

Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.

Wallerand H, Bakkar AA, de Medina SG, Pairon JC, Yang YC, Vordos D, Bittard H, Fauconnet S, Kouyoumdjian JC, Jaurand MC, Zhang ZF, Radvanyi F, Thiery JP, Chopin DK.

Carcinogenesis. 2005 Jan;26(1):177-84. Epub 2004 Sep 3.

PMID:
15347601
17.

Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.

Al-Kashwan TA, Houshmand M, Al-Janabi A, Melconian AK, Al-Abbasi D, Al-Musawi MN, Rostami M, Yasseen AA.

BMC Res Notes. 2012 Aug 28;5:466. doi: 10.1186/1756-0500-5-466.

18.

FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.

Smal MP, Rolevich AI, Polyakov SL, Krasny SA, Goncharova RI.

Exp Oncol. 2014 Dec;36(4):246-51.

PMID:
25537218
19.

High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins.

Zheng X, Zhuge J, Bezerra SM, Faraj SF, Munari E, Fallon JT 3rd, Yang XJ, Argani P, Netto GJ, Zhong M.

J Hematol Oncol. 2014 Jul 20;7:47. doi: 10.1186/s13045-014-0047-7.

20.

The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.

Yuan X, Liu C, Wang K, Liu L, Liu T, Ge N, Kong F, Yang L, Björkholm M, Fan Y, Zhao S, Xu D.

Oncotarget. 2016 May 3;7(18):25826-35. doi: 10.18632/oncotarget.8404.

Supplemental Content

Support Center